ConcertAI’s TeraRecon unveils pioneering AI advancements at RSNA23, bolstering clinical research and patient care. Their multi-modal AI platform, in collaboration with MSKCC, aims to revolutionize oncology research. Jeff Elton emphasizes the significance of multi-modal data AI and Generative AI for clinical trials and care strategies. The Pulmonology Suite adds to their AI algorithm collection, aiding clinicians in diagnosing pulmonary conditions. The event offers in-depth discussions, Doc Talks, and AI After Dark sessions, showcasing AI’s impact on healthcare. TeraRecon’s collaborations with AI partners highlight the diverse applications of AI in clinical settings.
ConcertAI’s TeraRecon presents groundbreaking AI innovations at RSNA23, aiming to reshape clinical research and patient care. Their cutting-edge advancements in AI, visualization, and expanded partnerships cater to complex clinical workflows. The collaboration with MSKCC reflects a strategic focus on enhancing oncology research using advanced AI methodologies. Jeff Elton emphasizes the critical role of multi-modal data AI and Generative AI in driving clinical trials and informed care strategies. Additionally, the Pulmonology Suite extends its AI algorithm offerings, empowering clinicians to make informed decisions for pulmonary conditions.
At RSNA 2023, ConcertAI and its TeraRecon clinical imaging solutions division have formally launched a pioneering multi-modal AI platform. This platform seamlessly integrates clinical, radiological, and digital pathology images, and real-world patient data to facilitate AI model development for clinical research, trials, and deploying AI models for prospective clinical validation.
A pivotal move in this realm involves ConcertAI’s multi-year strategic collaboration with Memorial Sloan Kettering Cancer Center (MSKCC). Focused on advancing Clinical AI in oncology, this partnership emphasizes fortifying clinical trials and refining oncology decision-making. Leveraging ConcertAI’s Eureka Life Science AI Platform, powered by TeraRecon, MSKCC will propel advancements in multi-modal AI workflows using clinical and radiological imaging data. The objective is to employ advanced data analysis and AI techniques to predict tumor mutations and treatment responses, thereby contributing significantly to the landscape of oncology research. The overarching goal is to elevate the role of Clinical AI in oncology research, expanding its benefits to more patients and institutions.
Jeff Elton, Ph.D., CEO of ConcertAI, emphasizes the significance of multi-modal data AI model development and validation, stressing their pivotal role in clinical trials and care. He emphasizes the need for tools that cater to biomedical researchers while harnessing the potential of Generative AI. Elton underscores the ground-up approach enabling multi-modal data management, AI model development, validation, and release. This strategy combines deep and extensive data scalability, an expansive research network, and state-of-the-art predictive AI and Gen AI, fostering widespread adoption within the research community.
ConcertAI’s TeraRecon also introduces the Pulmonology Suite, a comprehensive collection of leading, vendor-neutral AI algorithms. These algorithms aid in analyzing and interpreting Chest CT scans, offering insights to support clinicians in making informed decisions for pulmonary conditions such as pneumothorax, lung nodules, and incidental pulmonary embolism. This suite is a complementary addition to the previously launched Neurology Suite and Cardiology Suite earlier this year.
To learn more about these innovations and collaborations, attendees can schedule meetings or demonstrations at the main TeraRecon booth #8123 (North Hall) or the AI Showcase booth #4773 (South Hall) during RSNA.
Moreover, TeraRecon will facilitate various opportunities for RSNA attendees to engage with thought leaders, AI partners, and the local community. They’ll host a series of in-booth Doc Talks featuring expert physicians demonstrating how advanced imaging technology and AI are revolutionizing care delivery across multiple specialties.
Additionally, TeraRecon will organize the highly anticipated AI After Dark event—an evening gathering aimed at fostering engaging conversations about AI’s impact on healthcare. Esteemed panelists, including Dr. Giovanni Lorenz and Dr. Praveen Ranganath, will lead discussions around AI innovation in healthcare.
The RSNA AI Theater will feature a detailed conversation with partner Cercare Medical, focusing on the importance of AI partner ecosystems and their potential to enhance deployment efficiency for clinicians, IT infrastructure, and patient care.
Throughout the event, TeraRecon will showcase its 18 AI partners in booth #4773, offering presentations and demonstrations, providing a comprehensive look at the diverse applications of AI in healthcare.
Finally, in the spirit of giving, TeraRecon and Cercare Medical will host an Angel Tree in booth #8123, inviting attendees to contribute gifts benefiting patients at the Ann & Robert H. Lurie Children’s Hospital of Chicago.
Overall, TeraRecon’s presence at RSNA23 marks a milestone in AI integration, elevating clinical research and care solutions. Their multi-modal AI platform, in tandem with MSKCC, sets a precedent in advancing oncology research. Jeff Elton underscores the pivotal role of multi-modal data AI and Generative AI in shaping clinical trials and care pathways. The addition of the Pulmonology Suite broadens their AI algorithm repertoire for enhanced pulmonary diagnostics. Through engaging sessions and collaborations with AI partners, TeraRecon demonstrates the diverse applications and promising future of AI in revolutionizing healthcare.
